193 related articles for article (PubMed ID: 8975778)
21. High mobility group proteins stimulate DNA cleavage by apoptotic endonuclease DFF40/CAD due to HMG-box interactions with DNA.
Kalinowska-Herok M; Widłak P
Acta Biochim Pol; 2008; 55(1):21-6. PubMed ID: 18239742
[TBL] [Abstract][Full Text] [Related]
22. The recognition of distorted DNA structures by HMG-D: a footprinting and molecular modelling study.
Payet D; Hillisch A; Lowe N; Diekmann S; Travers A
J Mol Biol; 1999 Nov; 294(1):79-91. PubMed ID: 10556030
[TBL] [Abstract][Full Text] [Related]
23. Interaction between cisplatin-modified DNA and the HMG boxes of HMG 1: DNase I footprinting and circular dichroism.
Locker D; Decoville M; Maurizot JC; Bianchi ME; Leng M
J Mol Biol; 1995 Feb; 246(2):243-7. PubMed ID: 7869375
[TBL] [Abstract][Full Text] [Related]
24. Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein.
Imamura T; Izumi H; Nagatani G; Ise T; Nomoto M; Iwamoto Y; Kohno K
J Biol Chem; 2001 Mar; 276(10):7534-40. PubMed ID: 11106654
[TBL] [Abstract][Full Text] [Related]
25. Interactions between N- and C-terminal domains of the Saccharomyces cerevisiae high-mobility group protein HMO1 are required for DNA bending.
Bauerle KT; Kamau E; Grove A
Biochemistry; 2006 Mar; 45(11):3635-45. PubMed ID: 16533046
[TBL] [Abstract][Full Text] [Related]
26. The energetics of HMG box interactions with DNA: thermodynamics of the DNA binding of the HMG box from mouse sox-5.
Privalov PL; Jelesarov I; Read CM; Dragan AI; Crane-Robinson C
J Mol Biol; 1999 Dec; 294(4):997-1013. PubMed ID: 10588902
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
Zhai X; Beckmann H; Jantzen HM; Essigmann JM
Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin-DNA binding specificity of calf high-mobility group 1 protein.
Turchi JJ; Li M; Henkels KM
Biochemistry; 1996 Mar; 35(9):2992-3000. PubMed ID: 8608137
[TBL] [Abstract][Full Text] [Related]
29. Analysis of HMG protein binding to DNA modified with the anticancer drug cisplatin.
Cryer JE; Johnson SW; Engelsberg BN; Billings PC
Cancer Chemother Pharmacol; 1996; 38(2):163-8. PubMed ID: 8616907
[TBL] [Abstract][Full Text] [Related]
30. Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts.
Ohndorf UM; Whitehead JP; Raju NL; Lippard SJ
Biochemistry; 1997 Dec; 36(48):14807-15. PubMed ID: 9398202
[TBL] [Abstract][Full Text] [Related]
31. Nature of full-length HMGB1 binding to cisplatin-modified DNA.
Jung Y; Lippard SJ
Biochemistry; 2003 Mar; 42(9):2664-71. PubMed ID: 12614161
[TBL] [Abstract][Full Text] [Related]
32. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts.
Vaisman A; Lim SE; Patrick SM; Copeland WC; Hinkle DC; Turchi JJ; Chaney SG
Biochemistry; 1999 Aug; 38(34):11026-39. PubMed ID: 10460158
[TBL] [Abstract][Full Text] [Related]
33. Structural and kinetic studies of a cisplatin-modified DNA icosamer binding to HMG1 domain B.
Jamieson ER; Jacobson MP; Barnes CM; Chow CS; Lippard SJ
J Biol Chem; 1999 Apr; 274(18):12346-54. PubMed ID: 10212205
[TBL] [Abstract][Full Text] [Related]
34. Stopped-flow fluorescence studies of HMG-domain protein binding to cisplatin-modified DNA.
Jamieson ER; Lippard SJ
Biochemistry; 2000 Jul; 39(29):8426-38. PubMed ID: 10913248
[TBL] [Abstract][Full Text] [Related]
35. Intercalating residues determine the mode of HMG1 domains A and B binding to cisplatin-modified DNA.
He Q; Ohndorf UM; Lippard SJ
Biochemistry; 2000 Nov; 39(47):14426-35. PubMed ID: 11087395
[TBL] [Abstract][Full Text] [Related]
36. A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct.
Chow CS; Barnes CM; Lippard SJ
Biochemistry; 1995 Mar; 34(9):2956-64. PubMed ID: 7893709
[TBL] [Abstract][Full Text] [Related]
37. Recognition of platinum-induced DNA damage by nuclear proteins: screening for mechanisms.
Marples B; Adomat H; Billings PC; Farrell NP; Koch CJ; Skov KA
Anticancer Drug Des; 1994 Oct; 9(5):389-99. PubMed ID: 7945723
[TBL] [Abstract][Full Text] [Related]
38. HMG1 protein inhibits the translesion synthesis of the major DNA cisplatin adduct by cell extracts.
Hoffmann JS; Locker D; Villani G; Leng M
J Mol Biol; 1997 Jul; 270(4):539-43. PubMed ID: 9245584
[TBL] [Abstract][Full Text] [Related]
39. HMG box A in HMG2 protein functions as a mediator of DNA structural alteration together with box B.
Nakamura Y; Yoshioka K; Shirakawa H; Yoshida M
J Biochem; 2001 Apr; 129(4):643-51. PubMed ID: 11275566
[TBL] [Abstract][Full Text] [Related]
40. Differences in the DNA-binding properties of the HMG-box domains of HMG1 and the sex-determining factor SRY.
Teo SH; Grasser KD; Thomas JO
Eur J Biochem; 1995 Jun; 230(3):943-50. PubMed ID: 7601157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
